TOOLKIT

Thank you for registering for the 2022 POP-Q Workshop! Take the next step in managing various aspects of childhood neuroblastoma with the resources provided below. You can also watch each of the sessions here.

• CPIC Guidelines
  • CYP2D6 Genotype and Use of Ondansetron and Tropisetron
  • CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy
  • RYR1 or CACNA1S Genotypes and Anesthetics and Succinylcholine
• PHARMGKB Gene-Specific Information Tables
• Revised Neuroblastoma Classification System

• New Approaches to Neuroblastoma Therapy (NANT): The only clinical trials consortium in North America focused on developing new treatments and biomarkers for relapsed/refractory high-risk neuroblastoma
• Novel Therapies for Relapsed Refractory Neuroblastoma
• Naxitamab Administration Summary
• DFMO Administration Summary

• Prevention & Treatment of Anticipatory Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients
  • Clinical Practice Guideline Update 
  • Antiemetic Risk of Neuroblastoma Therapies
  • Children’s Hospital of Richmond Antiemetic Guidelines 
  • Use of Olanzapine
    • Naik RM, et al. Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial. J Clin Oncol 2020;38:3785
    • Moothedath AW, et al. Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Trial. J Pediatr Hematol Oncol 2022;44:446-53
• Dinutuximab Toxicity Management
  • Management of Dinutuximab Beta Adverse Events
  • Blom T, et al. Treatment Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients. Front Oncol 2021;10:601076
  • Barone G, et al. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance. Pediatric Drugs 2021;23:537-48
  • Bertolizio G, et al. Multimodal Analgesic Plan for Children Undergoing Chimeric 14.18 Immunotherapy. J Pediatr Hematol Oncol 2021;43:e169-72
• QTc Prolongation: Lim TR, et al. QTc Prolongation and Risk of Torsades de Pointes in Hospitalized Pediatric Oncology Patients. J Pediatr 2020;217:33-8

• Resources for Families: Neuroblastoma Cancer Society Survivorship Handbook
• Long-Term Follow-Up of High-Risk Neuroblastoma Survivors
• Cyclophosphamide Equivalent Dose (CED) Calculation
• Endocrine Effects & Infertility
  1. Infertility Risk based on CED 
  2. Cumulative Alkylating Exposure in NBL
  3. Geurten C, et al. Endocrine Consequences of Neuroblastoma Treatment in Children: 20 Years’ Experience of a Single Center. J Pediatr Endocrinol Metab 2019;32:347-54.
  4. Utriainen P, et al. Gonadal Failure is Common in Long-Term Survivors of Childhood High-Risk Neuroblastoma Treated with High-Dose Chemotherapy and Autologous Stem Cell Rescue. Front Endocrinol 2019;10:555. 
• Ototoxicity
  1. Ototoxicity Implications
  2. Otoxotoxicity Prevention Summary 
  3. Guidelines for Prevention of Cisplatin-Induced Ototoxicity: Freyer DR, et al. Prevention of Cisplatin-Induced Ototoxicity in Children and Adolescents with Cancer: A Clinical Practice Guideline. Lancet Child Adolesc Health 2020;4:141-50. 
  4. Meta-Analysis on Sodium Thiosulfate: Chen CH, et al. Association of Sodium Thiosulfate with Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis. JAMA Netw Open 2021;4:e2118895.
• Cardiotoxicity
  1. Anthracycline Dose Adjustments for Cardiotoxicity in NBL
  2. Cardiotoxic Chemotherapeutics in Peds: Hitawala G, et al. Pediatric Chemotherapy Drugs Associated with Cardiotoxicity. Cureus 2021;13:e19658.
  3. Use of Dexrazoxane: Reichardt P, et al. Risk-Benefit of Dexrazoxane for Preventing Anthracycline-Related Cardiotoxicity: Re-Evaluating the European Labeling. Future Oncol 2018;14:2663-2676.
• Currently Open Clinical Trial: COG ALTE15N2 – Late Effects After High-Risk Neuroblastoma (LEAHRN) 

• Eculizumab
  • Jodele S, et al. Complement Blockade for TA-TMA: Lessons Learned from a Large Pediatric Cohort Treated with Eculizumab. Blood 2020;135:1049-57
  • Eculizumab Dosing Algorithm 
  • Mizuno K, et al. Eculizumab Precision-Dosing Algorithm for Thrombotic Microangiopathy in Children and Young Adults Undergoing HSCT. Blood Advances 2022;6:1454-63
  • Eculizumab Precision Dosing Summary 
• Emerging Therapeutic and Preventative Approaches to Transplant-Associated TMA

Check out our toolkit from the 2021 POP-Q Workshop on AML here!